Prognostic implication of TIM-3 in clear cell renal cell carcinoma

Neoplasma

Volumn 61, Issue 1, 2014, Pages 35-40

  Yuan, J ^a   Jiang, B ^a   Zhao, H ^a   Huang, Q ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Clear cell renal cell carcinoma; Marker; Prognosis; TIM 3

Indexed keywords

KIDNEY INJURY MOLECULE 3; MEMBRANE PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CELL INVASION ASSAY; CONTROLLED STUDY; ELECTROPHORESIS; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MTT ASSAY; PARTIAL NEPHRECTOMY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; CARCINOMA, RENAL CELL; CELL PROLIFERATION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RNA, SMALL INTERFERING;

EID: 84893164076     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_006     Document Type: Article

References (17)

1. JEMAL A, BRAY F, CENTER MM, FERLAY J, WARD E, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90. http://dx.doi.org/10.3322/caac.20107
2. COHEN HT, MCGOVERN FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490. http://dx.doi.org/10.1056/NEJMra043172
3. FLANIGAN RC, SALMON SE, BLUMENSTEIN BA, BEARMAN SI, ROY V, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-1659. http://dx.doi.org/10.1056/NEJMoa003013
4. MCDERMOTT DF, REGAN MM, CLARK JI, FLAHERTY LE, WEISS GR, et al. Randomized phase III trial of highdose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141. http://dx.doi.org/10.1200/JCO.2005.03.206
5. MICKISCH GH, GARIN A, VAN POPPEL H, DE PRIJCK L, SYLVESTER R, et al. Radical nephrectomy plus interferonalfa-based immunotherapy compared with interferon alfa alone in metastatic renalcell carcinoma: a randomised trial. Lancet 2001; 358: 966-970. http://dx.doi.org/10.1016/S0140-6736(01)06103-7
6. SUN M, LUGHEZZANI G, PERROTTE P, KARAKIEWICZ PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol 2010; 7: 327-338. http://dx.doi.org/10.1038/nrurol.2010.57
7. ZHUANG X, ZHANG X, XIA X, ZHANG C, LIANG X, et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol 2012; 137: 978-985. http://dx.doi.org/10.1309/AJCP9Q6OVLVSHTMY
8. WIENER Z, KOHALMI B, POCZA P, JEAGER J, TOLGYESI G, et al. TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol 2007; 127: 906-914. http://dx.doi.org/10.1038/sj.jid.5700616
9. SAKUISHI K, APETOH L, SULLIVAN JM, BLAZAR BR, KUCHROO VK, et al. Targeting TIM-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-2194. http://dx.doi.org/10.1084/jem.20100643
10. FOURCADE J, SUN Z, BENALLAOUA M, GUILLAUME P, LUESCHER IF, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-2186. http://dx.doi.org/10.1084/jem.20100637
11. HUANG X, BAI X, CAO Y, WU J, HUANG M, et al. Lymphoma endothelium preferentially expresses TIM-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med 2010; 207: 505-520. http://dx.doi.org/10.1084/jem.20090397
12. GENG H, ZHANG GM, LI D, ZHANG H, YUAN Y, et al. Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol 2006; 176: 1411-1420.
13. CAI C, WANG L, WU Z, LI M, CHEN W, et al. T-cell immunoglobulin-and mucin-domain-containing molecule 3 gene polymorphisms and renal cell carcinoma. DNA Cell Biol 2012; 31: 1285-1289. http://dx.doi.org/10.1089/dna.2012.1625
14. JAN M, CHAO MP, CHA AC, ALIZADEH AA, GENTLES AJ, et al. Prospective separation of normal and leukemic stem cells based on differential expression of Tim-3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci 2011; 108: 5009-5014. http://dx.doi.org/10.1073/pnas.1100551108
15. KIKUSHIGE Y, SHIMA T, TAKAYANAGI S, URATA S, MIYAMOTO T, et al. Tim-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010; 7: 708-717. http://dx.doi.org/10.1016/j.stem.2010.11.014
16. YANG X, LIANG L, ZHANG XF, JIA HL, QIN Y, et al. Micro-RNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting IL-6-Stat3 pathway. Hepatology 2013 (in press) doi: 10.1002/hep.26305. http://dx.doi.org/10.1002/hep.26305
17. YUN UJ, PARK SE, JO YS, KIM J, SHIN DY. DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors. Cancer Lett 2012; 323: 155-160. http://dx.doi.org/10.1016/j.canlet.2012.04.003